Regulatory overview of biosimilars in Europe
Journal Title: International Journal of Drug Regulatory Affairs - Year 2018, Vol 6, Issue 3
Abstract
A biosimilar is a biological medicine similar, but not identical, to an already registered reference bio therapeutic product in terms of quality, safety, and efficacy. These drugs are also called as biosimilar products„, follow-on protein products‟ and subsequent-entry biologics„. The EU has pioneered the regulation of biosimilar medicines by establishing a solid framework for their approval and by shaping biosimilar development globally. Since the EU approved the first biosimilar in 2006, healthcare professionals have gained increasing experience with their use. Today, biosimilars are an integral part of the effective biological therapies available in the EU, supported by adequate safeguards protecting patient safety. In Europe, in 2001, legislation concerning biosimilar was codified as Directive 2001/83/EC to create a new marketing authorization procedure for similar biological medicinal products and also Committee for Medicinal Products for Human Use (CHMP) of the EMA is concern with these biosimilar products. The aim of biosimilars development is to demonstrate bio similarity - high similarity in terms of structure, biological activity and efficacy, safety and immunogenicity profile. Safety of biosimilars is monitored through pharmacovigilance activities, in the same way as for any other medicine. Biosimilars can offer advantages to EU healthcare systems, as it is expected to improve patients‟ access to safe and effective biological medicines with proven quality.
Authors and Affiliations
Shailaja Pashikanti, Jyothi Sri Durga V, Sowmya A. N. V. L
Keywords
Related Articles
- EP ID EP426949
- DOI 10.22270/ijdra.v6i3.270
- Views 126
- Downloads 0
A COMPREHENSION STUDY ON REGULATION OF HERBAL DRUGS IN USA, EUROPEAN UNION AND INDIA
The present study reviews the regulations of herbal drugs in the EU, US and India and throws light upon issues related to their clinical trials. Herbal drugs have been used for a long time in different systems of health...
General requirements for marketing authorization transfers in Thailand, Malaysia, Singapore, Indonesia and Philippines
The review article is only for brief idea about the Marketing Authorization Transfers in few of ASEAN region. Whatever the data here I have been provided is according to my knowledge and study depends on healthy authorit...
NANOPARTICULATE DRUG DELIVERY SYSTEM: A NOVEL APPROACH
As because of several advantages over to the conventional drug delivery Nanosparticulate drug delivery prepared in several means by several ways of methods have several applications in different discipline of Pharmaceuti...
QbD APPROACH FOR STABILITY INDICATING HPLC METHOD FOR DETERMINATION OF ARTEMETHER AND LUMEFANTRINE IN COMBINED DOSAGE FORM
The present paper reports a highly selective, sensitive and robust stability indicating RP-HPLC method using QbD approach, developed and validated for determination of Artemether and Lumefantrine in combined dosage form....
Pre-filled syringes in developed and developing region: An insight into Regulatory considerations
A Pre-filled syringe is a disposable syringe that is supplied already loaded with the substance to be injected. It is a unit dose of parenteral medication to which a needle has been fixed by a producer. They are small wh...